

Target Product Profile - Maternal vaccination

Variable	Minimal Requirement	Ideal Requirement
Primary Product Indication	Prevention of neonatal sepsis	Prevention of neonatal sepsis
Organisms Covered	<i>K. pneumoniae</i> , <i>E. coli</i> (ETEC or urinary), <i>A. baumannii</i> or <i>S. aureus</i> , with coverage of 70% of clinical isolates	<i>K. pneumoniae</i> , <i>E. coli</i> (ETEC or urinary), <i>A. baumannii</i> or <i>S. aureus</i> , with 90% of clinical isolates
Target Population	Pregnant women in LMICs	Pregnant women in LMICs
Modality	Quantitatively optimized composition	Quantitatively optimized composition
Protection Duration	1 month	3 months
Delivery Mode	IM	IM
Dosage Form	Single dose vial	Multi-dose vial/syringe
Regimen	One maternal administration at Week 36	One maternal administration at Week 27
Efficacy	50%	70%
Risk/Side Effects	Local, mild AEs only in mother, none in neonate	Local, mild AEs only, none in neonate
Stability	1 year at 4C	1 month at 37C
Cost	1-5\$/dose	<1\$/dose
Specific Population Claims		HIV-infected populations